# Albumin

## Albumin inj 20% 50mL \(TBSF\)

| 藥物代碼 | IALB20 |
| :--- | :--- |
| 適應症 | Hypovolemic shock, conditions when there is severe hypoalbuminemia, as an adjunct in hemodialysis & in cardiopulmonary bypass procedures. In conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. |
| 副作用 | Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution, and pulmonary edema. SeriousEndocrine metabolic: HypovolemiaImmunologic: Hypersensitivity reaction |
| 禁忌 | History of hypersensitivity reaction to albumin preparations or to any component of the product. Patients with severe anemia or cardiac failure with normal or increased intravascular volume. Patients at risk for circulatory overload \(eg, history of congestive cardiac failure, renal insufficiency, or stabilized chronic anemia\). Patients with chronic kidney disease injected with 20% albumin solution will be rapidly excreted by the kidneys and cannot relieve chronic edema. Not suitable for hypoalbuminemia caused by chronic liver cirrhosis, malabsorption, intestinal protein loss, pancreatic insufficiency and malnutrition. |
| 藥物保存方式 | 30°C 以下 |
| 用法用量 | Hypoproteinaemia in the acutely ill patient The usual daily dose is 50–75 g human albumin \(250-375 mL of “TBSF” \(20%\) Human Albumin Solution\). The rate of administration should not exceed 2 mL per minute, as more rapid infusion may precipitate circulatory overload and pulmonary edema. The infusion of “TBSF” \(20%\) Human Albumin Solution is not justified in hypoproteinaemic states associated with chronic cirrhosis, malabsorption, protein-losing enteropathies, pancreatic insufficiency, or undernutrition. Shock The dose should be determined by the patient’s condition and response to treatment. The usual initial dose of 20 g human albumin \(100 mL of “TBSF” \(20%\) Human Albumin Solution\) may be administered as a blood volume expander at a rate of 2 to 4 mL per minute. The rate of infusion may be increased in emergencies and repeated in 15 to 30 minutes if necessary. The total dose should not exceed the level of albumin found in the normal individual i.e. about 2 g per kg body weight in the absence of active bleeding. If concentrated albumin \(&gt;4–5%\) is given, it should be accompanied by the intravenous infusion of a crystalloid solution. Failure to supply this additional fluid may lead to dehydration of the tissues. The precise nature and strength of the crystalloid solution will depend on the requirements of the patient for electrolytes and fluid. Burns The usual dose is 20-80 g human albumin \(100-400 mL of “TBSF” \(20%\) Human Albumin Solution\) given daily at the rate of about 1 mL per minute. Beyond 24 hours, “TBSF” \(20%\) Human Albumin Solution can be used to maintain plasma colloid osmotic pressure. A reasonable goal is the maintenance of a plasma albumin concentration of 25 g/L or a colloid osmotic pressure of 20 mmHg. The continuing need for albumin is occasioned by losses from denuded areas and decreased albumin synthesis. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]尚未有“國血製劑益康”\(20%\)人血清白蛋白注射劑在動物生殖毒性的研究。 因為在動物模式中會對人類白蛋白產生抗體而無法進行此研究。 在懷孕期間使用“國血製劑益康”\(20%\)人血清白蛋白注射劑，尚未建立於對照臨床試驗中確立， 因此，如有明確的需要才可給予孕婦。 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]與內生性血清白蛋白相似， “國血製劑益康”\(20%\)人血清白蛋白注射劑可能分泌至乳汁。 尚無此方面的安全資訊。 |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選  【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 國血製劑益康\(20%\)人血清白蛋白注射劑可稀釋成等膠體滲透壓之蛋白質溶液\(4~5%白蛋白\)，其比例為1mL國血製劑益康\(20%\)人血清白蛋白注射劑比4mL晶體溶液，再以平常的靜脈注射法給予。 輸注速率： 急性病人的低蛋白血症：&lt;2mL/分鐘 休克\(當做血液體積的擴張劑\)：2-4mL/分鐘 燒傷：1mL/分鐘 |
| 注意事項 | 1.若須稀釋須使用晶體溶液，但仿單中無建議之溶液，廠商亦無法提供相容性文件。 2.不可用水來稀釋，因為其低滲透壓會導致血管內溶血。 3.本產品不含任何抗微生物防腐劑，因此，在開瓶後應馬上使用。 4.切勿使用曾經被冷凍過的溶液。 |

